EMEA-001397-PIP06-17

Key facts

Invented name
Imbruvica
Active substance
Ibrutinib
Therapeutic area
Oncology
Decision number
P/0297/2017
PIP number
EMEA-001397-PIP06-17
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of lymphoplasmacytic lymphoma
Route(s) of administration
Oral use
Contact for public enquiries
Janssen-Cilag International N.V.
Tel.: +49 2638 9479218
E-mail: sglawe@its.jnj.com
 
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating